Trade Report: Today, TIAA CREF Trust Co. FSB MO invests in Novo Nordisk A/S (NVO) Shares

Today, TIAA CREF Trust Co. FSB MO invests in Novo Nordisk A/S (NVO) Shares

TIAA CREF Trust Co. FSB MO increased its position in Novo Nordisk A/S (NYSE:NVO) by 4.7% during the third quarter, Holdings Channel reports. The institutional investor owned 19,850 shares of the company’s stock after buying an additional 887 shares during the period. TIAA CREF Trust Co. FSB MO’s holdings in Novo Nordisk A/S were worth $826,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Jennison Associates LLC increased its position in shares of Novo Nordisk A/S by 16.4% in the second quarter. Jennison Associates LLC now owns 17,400,801 shares of the company’s stock worth $935,815,000 after buying an additional 2,452,120 shares in the last quarter. Loomis Sayles & Co. L P increased its stake in Novo Nordisk A/S by 6.3% in the second quarter. Loomis Sayles & Co. L P now owns 11,847,603 shares of the company’s stock worth $637,164,000 after buying an additional 705,851 shares during the period. WCM Investment Management CA increased its stake in Novo Nordisk A/S by 5.2% in the third quarter. WCM Investment Management CA now owns 9,238,271 shares of the company’s stock worth $384,220,000 after buying an additional 458,749 shares during the period. Saratoga Research & Investment Management increased its stake in Novo Nordisk A/S by 50.3% in the third quarter. Saratoga Research & Investment Management now owns 1,198,699 shares of the company’s stock worth $49,854,000 after buying an additional 401,267 shares during the period. Finally, First Trust Advisors LP increased its stake in Novo Nordisk A/S by 2,299.0% in the third quarter. First Trust Advisors LP now owns 299,821 shares of the company’s stock worth $12,470,000 after buying an additional 287,323 shares during the period. 7.34% of the stock is owned by institutional investors.

Novo Nordisk A/S (NYSE:NVO) traded up 1.37% on Monday, hitting $32.52. 1,935,525 shares of the stock traded hands. The stock has a 50-day moving average price of $36.56 and a 200 day moving average price of $47.31. The company has a market cap of $82.16 billion, a price-to-earnings ratio of 15.52 and a beta of 0.84. Novo Nordisk A/S has a 1-year low of $30.89 and a 1-year high of $59.00.

A number of equities research analysts recently weighed in on the stock. Bank of America Corp. set a $57.00 price target on shares of Novo Nordisk A/S and gave the stock a “hold” rating in a research note on Saturday, September 17th. Jefferies Group reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Wednesday, September 14th. DNB Markets downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, October 31st. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Thursday, October 13th. Finally, Citigroup Inc. reissued a “buy” rating on shares of Novo Nordisk A/S in a research note on Wednesday, August 3rd. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $61.33.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

Related posts

Leave a Comment